Vivani Medical SEC Filings

Vivani Medical (VANI) director and 10% owner Gregg G. Williams reported purchasing 3,703,703 shares of common stock on 10/27/2025 at $1.62 per share in a private sale transaction under a Share Purchase Agreement dated 10/26/2025. The transaction totaled $5,999,998.86.

Following the trade, Williams beneficially owned 26,150,015 shares, comprising 4,799,200 held directly and 21,350,815 held indirectly.

Vivani Medical (VANI) secured new capital through two equity transactions. The company completed a private placement of 3,703,703 common shares at $1.62 per share, generating approximately $6.0 million in gross proceeds. No warrants, discounts, or placement fees were involved.

Concurrently, Vivani entered a registered direct offering for 6,000,000 common shares, with gross proceeds of approximately $9.7 million, before a 7.0% placement fee and up to $125,000 of reimbursable expenses paid to ThinkEquity. Directors and officers agreed to 60-day lock-ups from the closing of the registered offering. The registered sale is being made under the company’s effective Form S-3 shelf via a prospectus and prospectus supplement.

Vivani Medical, Inc. launched a registered direct offering of 6,000,000 shares of common stock at $1.62 per share. The company expects gross proceeds of $9,720,000, placement agent fees of 7.0%, and estimates net proceeds of approximately $8.7 million from this offering, with closing expected on or about October 28, 2025 subject to customary conditions.

Concurrently, an entity affiliated with director Gregg Williams agreed to purchase 3,703,703 shares in a separate private placement at the same price, generating an estimated additional $5.9 million in net proceeds; this sale is not part of the registered offering and carries no underwriting discounts or commissions. Combined net proceeds are approximately $14.7 million. Shares outstanding are expected to be 72,952,235 after the offering and concurrent private placement. Proceeds will fund research and clinical development, working capital, capital expenditures, and general corporate purposes, with management indicating funding into 2027.

Vivani Medical (VANI) insider filed a Form 4 reporting open-market style private purchases. On 10/15/2025, the reporting person, a Director and 10% Owner, acquired 1,473,214 shares at $1.12 per share pursuant to a Share Purchase Agreement dated March 26, 2025, and 264,550 shares at $1.26 per share pursuant to a Share Purchase Agreement dated August 11, 2025.

Following these transactions, beneficial ownership stood at 17,647,112 shares held indirectly and 4,799,200 shares held directly, for a combined 22,446,312 shares with voting and dispositive power over all such shares.

Vivani Medical, Inc. reported that it has temporarily withdrawn the previously announced October 8, 2025 record date for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The change was announced on October 3, 2025 and is attributed to delays arising from the current shutdown of the U.S. federal government.

Cortigent is developing brain implant devices using neuromodulation technology, and the spin-off remains proposed, but the timing of determining which shareholders would be eligible to receive shares is now on hold until a new record date is set.

Gregg Williams, a director and reported 10% owner of Vivani Medical, Inc. (VANI), purchased shares in two private transactions during 2025. On 03/26/2025 he bought 1,473,215 shares at $1.12 per share (gross $1,650,000.80). On 08/11/2025 he bought 595,238 shares at $1.26 per share (gross $749,999.88). Following the reported transactions dated 09/15/2025, the filing shows beneficial ownership totaling 20,708,548 shares, with a detailed breakdown across trusts and entities for which he has voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 09/17/2025.

Vivani Medical, Inc. is moving forward with its previously announced spin-off of its wholly owned subsidiary, Cortigent, Inc., which develops brain implant devices using neuromodulation technology. The company has set October 8, 2025 as the record date for the transaction. Stockholders who hold Vivani common stock as of that date will be entitled to receive Cortigent common stock when the spin-off is completed. The company stated that the distribution date and the share dividend ratio for Cortigent stock will be announced at a later time. Vivani also issued a press release on September 17, 2025, describing this update.

Vivani Medical, Inc. filed a current report to furnish its latest corporate slide presentation to the investment community. The slide deck, dated September 9, 2025, is attached as Exhibit 99.1 and is also available in the Investors section of the company’s website.

The slides are provided under Regulation FD as investor information and are deemed “furnished,” not “filed,” which limits their use for certain securities law liability purposes. Vivani notes the slides speak only as of their date and expressly disclaims any obligation to update them.

Vivani Medical, Inc. announced on September 4, 2025 that it has outlined clinical development plans for NPM-139, its investigational semaglutide implant intended for chronic weight management in patients who are obese or overweight with a related comorbidity. The disclosure is furnished as an exhibit (Press Release, Exhibit 99.1) to this Current Report and does not include financial metrics, timelines, enrollment targets, regulatory milestones, or expected costs. The filing is signed by Donald Dwyer, Chief Business Officer.